nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—Dyspnoea—Sorafenib—thyroid cancer	0.00199	0.00199	CcSEcCtD
Anagrelide—Lymphadenopathy—Epirubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Anagrelide—Nausea—Vandetanib—thyroid cancer	0.00196	0.00196	CcSEcCtD
Anagrelide—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00196	0.00196	CcSEcCtD
Anagrelide—Dyspepsia—Sorafenib—thyroid cancer	0.00196	0.00196	CcSEcCtD
Anagrelide—Decreased appetite—Sorafenib—thyroid cancer	0.00194	0.00194	CcSEcCtD
Anagrelide—Ecchymosis—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00193	0.00193	CcSEcCtD
Anagrelide—Fatigue—Sorafenib—thyroid cancer	0.00192	0.00192	CcSEcCtD
Anagrelide—Photosensitivity—Epirubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Anagrelide—Pain—Sorafenib—thyroid cancer	0.00191	0.00191	CcSEcCtD
Anagrelide—Constipation—Sorafenib—thyroid cancer	0.00191	0.00191	CcSEcCtD
Anagrelide—Abnormal vision—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Anagrelide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Anagrelide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00182	0.00182	CcSEcCtD
Anagrelide—Lymphadenopathy—Doxorubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Anagrelide—Urticaria—Sorafenib—thyroid cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Photosensitivity—Doxorubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Abdominal pain—Sorafenib—thyroid cancer	0.00176	0.00176	CcSEcCtD
Anagrelide—Body temperature increased—Sorafenib—thyroid cancer	0.00176	0.00176	CcSEcCtD
Anagrelide—Renal impairment—Epirubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Anagrelide—Cardiac failure—Epirubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Anagrelide—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Osteoarthritis—Epirubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Anagrelide—Diplopia—Epirubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Anagrelide—Migraine—Epirubicin—thyroid cancer	0.00165	0.00165	CcSEcCtD
Anagrelide—Renal impairment—Doxorubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Anagrelide—Asthenia—Sorafenib—thyroid cancer	0.0016	0.0016	CcSEcCtD
Anagrelide—Cardiac failure—Doxorubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Anagrelide—Pruritus—Sorafenib—thyroid cancer	0.00158	0.00158	CcSEcCtD
Anagrelide—Blood creatinine increased—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Anagrelide—Dehydration—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Anagrelide—Osteoarthritis—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Anagrelide—Diplopia—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Anagrelide—Liver function test abnormal—Epirubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Anagrelide—Dry skin—Epirubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Anagrelide—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Migraine—Doxorubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Diarrhoea—Sorafenib—thyroid cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Gastritis—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Anagrelide—Dizziness—Sorafenib—thyroid cancer	0.00147	0.00147	CcSEcCtD
Anagrelide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Dysphagia—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Asthma—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Influenza—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Dehydration—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Anagrelide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Anagrelide—Dry skin—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Pancreatitis—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Vomiting—Sorafenib—thyroid cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Angina pectoris—Epirubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Rash—Sorafenib—thyroid cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Dermatitis—Sorafenib—thyroid cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Headache—Sorafenib—thyroid cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Bronchitis—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Pancytopenia—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Anagrelide—Gastritis—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Anagrelide—Dysuria—Epirubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Anagrelide—Dysphagia—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Asthma—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Influenza—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Pollakiuria—Epirubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Nausea—Sorafenib—thyroid cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Weight increased—Epirubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Pancreatitis—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Weight decreased—Epirubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Pneumonia—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Renal failure—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Conjunctivitis—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Urinary tract infection—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Anagrelide—Sweating—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Anagrelide—Haematuria—Epirubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Epistaxis—Epirubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Sinusitis—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Anagrelide—Haemoglobin—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Anagrelide—Rhinitis—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Haemorrhage—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Hepatitis—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Hypoaesthesia—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Pharyngitis—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Urinary tract disorder—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Oedema peripheral—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Anagrelide—Mediastinal disorder—Epirubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Anagrelide—Chills—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Arrhythmia—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—thyroid cancer	0.000996	0.000996	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—thyroid cancer	0.000995	0.000995	CcSEcCtD
Anagrelide—Tension—Epirubicin—thyroid cancer	0.000991	0.000991	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—thyroid cancer	0.000981	0.000981	CcSEcCtD
Anagrelide—Back pain—Epirubicin—thyroid cancer	0.000977	0.000977	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—thyroid cancer	0.000971	0.000971	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000967	0.000967	CcSEcCtD
Anagrelide—Chills—Doxorubicin—thyroid cancer	0.000963	0.000963	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—thyroid cancer	0.000959	0.000959	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—thyroid cancer	0.000952	0.000952	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—thyroid cancer	0.000948	0.000948	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000937	0.000937	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—thyroid cancer	0.000934	0.000934	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—thyroid cancer	0.000933	0.000933	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—thyroid cancer	0.000921	0.000921	CcSEcCtD
Anagrelide—Tension—Doxorubicin—thyroid cancer	0.000917	0.000917	CcSEcCtD
Anagrelide—Malaise—Epirubicin—thyroid cancer	0.000911	0.000911	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—thyroid cancer	0.000907	0.000907	CcSEcCtD
Anagrelide—Syncope—Epirubicin—thyroid cancer	0.000906	0.000906	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—thyroid cancer	0.000904	0.000904	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—thyroid cancer	0.000898	0.000898	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—thyroid cancer	0.000892	0.000892	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—thyroid cancer	0.000888	0.000888	CcSEcCtD
Anagrelide—Cough—Epirubicin—thyroid cancer	0.000881	0.000881	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—thyroid cancer	0.000881	0.000881	CcSEcCtD
Anagrelide—Convulsion—Epirubicin—thyroid cancer	0.000875	0.000875	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—thyroid cancer	0.000872	0.000872	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000867	0.000867	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—thyroid cancer	0.000864	0.000864	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—thyroid cancer	0.00086	0.00086	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—thyroid cancer	0.00086	0.00086	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—thyroid cancer	0.00086	0.00086	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000854	0.000854	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—thyroid cancer	0.000849	0.000849	CcSEcCtD
Anagrelide—Malaise—Doxorubicin—thyroid cancer	0.000843	0.000843	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—thyroid cancer	0.000841	0.000841	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—thyroid cancer	0.000838	0.000838	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—thyroid cancer	0.000831	0.000831	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—thyroid cancer	0.000826	0.000826	CcSEcCtD
Anagrelide—Oedema—Epirubicin—thyroid cancer	0.000824	0.000824	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—thyroid cancer	0.000821	0.000821	CcSEcCtD
Anagrelide—Infection—Epirubicin—thyroid cancer	0.000819	0.000819	CcSEcCtD
Anagrelide—Cough—Doxorubicin—thyroid cancer	0.000815	0.000815	CcSEcCtD
Anagrelide—Shock—Epirubicin—thyroid cancer	0.000811	0.000811	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—thyroid cancer	0.00081	0.00081	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—thyroid cancer	0.000808	0.000808	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000807	0.000807	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—thyroid cancer	0.000807	0.000807	CcSEcCtD
Anagrelide—Tachycardia—Epirubicin—thyroid cancer	0.000804	0.000804	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—thyroid cancer	0.000801	0.000801	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000797	0.000797	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—thyroid cancer	0.000795	0.000795	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—thyroid cancer	0.000795	0.000795	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—thyroid cancer	0.000795	0.000795	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00079	0.00079	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—thyroid cancer	0.000786	0.000786	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—thyroid cancer	0.000786	0.000786	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—thyroid cancer	0.000778	0.000778	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—thyroid cancer	0.00077	0.00077	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—thyroid cancer	0.000769	0.000769	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—thyroid cancer	0.000763	0.000763	CcSEcCtD
Anagrelide—Infection—Doxorubicin—thyroid cancer	0.000758	0.000758	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000751	0.000751	CcSEcCtD
Anagrelide—Shock—Doxorubicin—thyroid cancer	0.00075	0.00075	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000748	0.000748	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000747	0.000747	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—thyroid cancer	0.000745	0.000745	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—thyroid cancer	0.000744	0.000744	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—thyroid cancer	0.000741	0.000741	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—thyroid cancer	0.00074	0.00074	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000737	0.000737	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—thyroid cancer	0.000735	0.000735	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—thyroid cancer	0.000733	0.000733	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—thyroid cancer	0.000727	0.000727	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—thyroid cancer	0.000725	0.000725	CcSEcCtD
Anagrelide—Decreased appetite—Epirubicin—thyroid cancer	0.000716	0.000716	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—thyroid cancer	0.000713	0.000713	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000712	0.000712	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—thyroid cancer	0.000711	0.000711	CcSEcCtD
Anagrelide—Constipation—Epirubicin—thyroid cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Pain—Epirubicin—thyroid cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000695	0.000695	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—thyroid cancer	0.00069	0.00069	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—thyroid cancer	0.000685	0.000685	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—thyroid cancer	0.00068	0.00068	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—thyroid cancer	0.000679	0.000679	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—thyroid cancer	0.000678	0.000678	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000674	0.000674	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—thyroid cancer	0.000671	0.000671	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—thyroid cancer	0.000663	0.000663	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000658	0.000658	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—thyroid cancer	0.000657	0.000657	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—thyroid cancer	0.000655	0.000655	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—thyroid cancer	0.000652	0.000652	CcSEcCtD
Anagrelide—Pain—Doxorubicin—thyroid cancer	0.000652	0.000652	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—thyroid cancer	0.000651	0.000651	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—thyroid cancer	0.000651	0.000651	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000628	0.000628	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000624	0.000624	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—thyroid cancer	0.000606	0.000606	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—thyroid cancer	0.000603	0.000603	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—thyroid cancer	0.000603	0.000603	CcSEcCtD
Anagrelide—Asthenia—Epirubicin—thyroid cancer	0.000591	0.000591	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—thyroid cancer	0.000583	0.000583	CcSEcCtD
Anagrelide—Diarrhoea—Epirubicin—thyroid cancer	0.000564	0.000564	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—thyroid cancer	0.000547	0.000547	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—thyroid cancer	0.000545	0.000545	CcSEcCtD
Anagrelide—Pruritus—Doxorubicin—thyroid cancer	0.00054	0.00054	CcSEcCtD
Anagrelide—Vomiting—Epirubicin—thyroid cancer	0.000524	0.000524	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—thyroid cancer	0.000522	0.000522	CcSEcCtD
Anagrelide—Rash—Epirubicin—thyroid cancer	0.00052	0.00052	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—thyroid cancer	0.000519	0.000519	CcSEcCtD
Anagrelide—Headache—Epirubicin—thyroid cancer	0.000516	0.000516	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—thyroid cancer	0.000504	0.000504	CcSEcCtD
Anagrelide—Nausea—Epirubicin—thyroid cancer	0.00049	0.00049	CcSEcCtD
Anagrelide—Vomiting—Doxorubicin—thyroid cancer	0.000485	0.000485	CcSEcCtD
Anagrelide—Rash—Doxorubicin—thyroid cancer	0.000481	0.000481	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—thyroid cancer	0.00048	0.00048	CcSEcCtD
Anagrelide—Headache—Doxorubicin—thyroid cancer	0.000478	0.000478	CcSEcCtD
Anagrelide—Nausea—Doxorubicin—thyroid cancer	0.000453	0.000453	CcSEcCtD
